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BMD

:   bone mineral density

BMI

:   body mass index

DXA

:   dual‐energy X‐ray absorptiometry

ETPKU

:   early treated PKU

FNBMD

:   femoral neck bone mineral density

ISCD

:   International Society for Clinical Densitometry

LBMD

:   lumbar bone mineral density

PAH

:   phenylalanine hydroxylase

Phe

:   phenylalanine

PKU

:   phenylketonuria

RBMD

:   radius bone mineral density

TBMD

:   total body bone mineral density

TFBMD

:   total proximal femur bone mineral density

1. INTRODUCTION {#jimd12177-sec-0002}
===============

Phenylketonuria (PKU, ORPHA79254, MIM 261600) is an inborn error of metabolism in which deficiency of the enzyme phenylalanine hydroxylase (PAH; EC 1.14.16.1) causes high phenylalanine (Phe) concentrations which lead to intellectual disability if left untreated. Since the 1960\'s‐1970\'s, patients are detected early by newborn screening and treatment with a Phe‐restricted diet is started immediately. This results in a near normal outcome of development. However, as the first early treated PKU (ETPKU) patients become older, new concerns about long term consequences of PKU and its treatment arise.[1](#jimd12177-bib-0001){ref-type="ref"}, [2](#jimd12177-bib-0002){ref-type="ref"}, [3](#jimd12177-bib-0003){ref-type="ref"}, [4](#jimd12177-bib-0004){ref-type="ref"} Most attention is given to the neurocognitive issues and psychosocial functioning, but also bone health has been a long‐standing concern in PKU patients.[3](#jimd12177-bib-0003){ref-type="ref"}, [4](#jimd12177-bib-0004){ref-type="ref"} It is hypothesised that the Phe restricted diet or the disease itself might lead to a low bone mineral density (BMD) in PKU. However, previous studies show conflicting results due to differences in assessing BMD and different criteria for defining low BMD.[4](#jimd12177-bib-0004){ref-type="ref"}, [5](#jimd12177-bib-0005){ref-type="ref"}, [6](#jimd12177-bib-0006){ref-type="ref"}, [7](#jimd12177-bib-0007){ref-type="ref"}, [8](#jimd12177-bib-0008){ref-type="ref"}, [9](#jimd12177-bib-0009){ref-type="ref"}, [10](#jimd12177-bib-0010){ref-type="ref"}, [11](#jimd12177-bib-0011){ref-type="ref"}, [12](#jimd12177-bib-0012){ref-type="ref"}, [13](#jimd12177-bib-0013){ref-type="ref"} Furthermore, most studies included a small number of patients. In 2015, the meta‐analysis by Demirdas and colleagues showed that low BMD for chronological age, defined as a *Z*‐score [\<]{.ul}−2 (in agreement with the International Society for Clinical Densitometry (ISCD) criteria) is expected in approximately 10% of ETPKU patients.[8](#jimd12177-bib-0008){ref-type="ref"}, [14](#jimd12177-bib-0014){ref-type="ref"} However, most of the studies included in this meta‐analysis focused on BMD in both adult and paediatric patients, with only one small study focusing solely on adult patients.[15](#jimd12177-bib-0015){ref-type="ref"} Including the results of BMD in paediatric patients might distort the information about adult patients for several reasons. Factors like bone development, growth, puberty, and body composition all affect (assessment of) BMD.[16](#jimd12177-bib-0016){ref-type="ref"}, [17](#jimd12177-bib-0017){ref-type="ref"} In addition peak bone mass is attained during late adolescence/early adulthood.[18](#jimd12177-bib-0018){ref-type="ref"} Therefore, there is a need for the assessment of BMD in a large cohort of adult ETPKU patients. Insight in BMD of adults with PKU will determine further need for follow up.

The aim of the presented multicentre survey study was to collect retrospective data for assessment of the prevalence of low BMD and to define possible risk factors for low BMD in a large number of adult, ETPKU patients.

2. METHODS {#jimd12177-sec-0003}
==========

Seventeen European centres specialised in treating adult PKU patients were invited to participate in a survey study collecting retrospective data of individual adult ETPKU patients. Participating centres were asked to complete a questionnaire for all early treated (start treatment \<4 weeks of age), adult ([\>]{.ul}18 years) PKU patients of whom data of dual‐energy X‐ray absorptiometry (DXA) was available. Exclusion criteria were chronic conditions affecting bone health; chronic malabsorption disease, chronical use of steroids (\>5 mg of prednisolone daily for 3 months or longer), rheumatoid arthritis, immobility, hypogonadism, organ transplantation, type 1 diabetes mellitus, thyroid disorders, chronic obstructive pulmonary disease as well as a postmenopausal state.[14](#jimd12177-bib-0014){ref-type="ref"}, [18](#jimd12177-bib-0018){ref-type="ref"}, [19](#jimd12177-bib-0019){ref-type="ref"}, [20](#jimd12177-bib-0020){ref-type="ref"}

The questionnaire included deindentified data involving demographics, anthropometrics, diet, and supplements, mean Phe (μmol/L) during the year before the recent DXA scan (one centre included mean Phe of the 2 years before the recent DXA scan), use of sapropterin dichloride, low vitamin D concentration (defined as 25‐OH vitamin D \<50 nmol/L),[21](#jimd12177-bib-0021){ref-type="ref"} (number of) fractures, smoking or ex‐smoker status, and alcohol consumption.

The (most recent) DXA results in *Z*‐score were collected for different skeletal sites; lumbar (LBMD), femoral neck (FNBMD), total proximal femur (TFBMD), radius (RBMD), and total body (TBMD). According to the ISCD criteria *Z‐*scores and not *T*‐scores were used as the studied patients involved premenopausal women and men \<50 years of age. A BMD *Z*‐score [\<]{.ul}−2 SD was defined as below the expected range for age (low BMD), and a *Z*‐score \>−2 was defined as within the expected range for age.[14](#jimd12177-bib-0014){ref-type="ref"}

Data was collected in Castor EDC, a good clinical practice compliant data management system.

The medical ethics committee of the Amsterdam UMC, AMC, Amsterdam, The Netherlands, confirmed that for this survey study collecting retrospective data the Medical Research Involving Human Subjects Act (WMO) did not apply and informed consent was not required. This article does not contain any studies with human or animal subjects performed by any of the authors.

2.1. Statistical analysis {#jimd12177-sec-0004}
-------------------------

Sample size calculation by the Lehr\'s formula[22](#jimd12177-bib-0022){ref-type="ref"} revealed that a sample size of at least 80 patients (after correction for unequal sized groups[23](#jimd12177-bib-0023){ref-type="ref"}) was sufficient to yield 80% power to detect a difference of at least 7.6% in prevalence of low BMD in ETPKU patients compared to the general population with a type I error of 5%, based on the available data by Demirdas et al.[8](#jimd12177-bib-0008){ref-type="ref"}

Analysis was performed using IBM SPSS statistics 23. Normally distributed data was compared by parametric tests (one sample *t* test or unpaired *t* test), non‐normally distributed data was analysed by non‐parametric tests (Wilcoxon signed rank test or Mann‐Whitney *U* test). Categorical data was analysed by a *χ* ^2^or Fishers Exact test. In case of multiple hypothesis testing, a post‐hoc analysis was done by the Bonferroni method (multiplying *P*‐value by the number of tests). A *P*‐value \<.05 was considered statistically significant.[22](#jimd12177-bib-0022){ref-type="ref"}, [24](#jimd12177-bib-0024){ref-type="ref"}, [25](#jimd12177-bib-0025){ref-type="ref"}

In case of multiple DXA scans in one patient, the most recent was selected for analysis. Mean BMD (*Z*‐score) was assessed for the different skeletal sites and compared to the expected mean *Z*‐score (0) in the general population. Frequency of low BMD was calculated.

The spine and hip region are the sites of preference to measure BMD.[14](#jimd12177-bib-0014){ref-type="ref"}, [19](#jimd12177-bib-0019){ref-type="ref"} Several possible risk factors were taken into consideration when comparing patients with a low BMD at the spine level and those with a BMD within normal range. They included; gender, age at time most recent DXA, recent Body Mass Index, natural protein intake, use of calcium and vitamin D supplements, use of sapropterin dichloride, mean Phe the year before the recent DXA scan, low vitamin D concentration, and life style factors (smoking and alcohol consumption).[4](#jimd12177-bib-0004){ref-type="ref"}, [7](#jimd12177-bib-0007){ref-type="ref"}, [10](#jimd12177-bib-0010){ref-type="ref"}, [11](#jimd12177-bib-0011){ref-type="ref"}, [12](#jimd12177-bib-0012){ref-type="ref"}, [13](#jimd12177-bib-0013){ref-type="ref"}, [18](#jimd12177-bib-0018){ref-type="ref"}, [19](#jimd12177-bib-0019){ref-type="ref"}, [26](#jimd12177-bib-0026){ref-type="ref"} Not for all patients with a statement of normal diet the exact amount of natural protein intake was available. Before statistical analysis was performed, natural protein intake was categorised according to the following groups; (a) missing or not adherent to a diet, (b) severe protein restriction ([\<]{.ul}10 g/day), (c) moderate protein restriction (\>10 to 20 g/day), (d) mild protein restriction (\>20 to 40 g/day), (e) protein intake \> recommended intake (\>40 g/day). An amount of \>40 g was based on the safe amount of protein of 0.8 g/kg/day according to FAO/WHO/UNU with some patients weighing around 50 kg.[3](#jimd12177-bib-0003){ref-type="ref"}

Frequency of fractures was compared to the estimated age‐standardised fracture prevalence as described for England.[27](#jimd12177-bib-0027){ref-type="ref"}

3. RESULTS {#jimd12177-sec-0005}
==========

A total of 8 (out of 17 invited) European metabolic centres, situated in France, Poland, Spain, the Netherlands, and the United Kingdom, participated in the study. Among 9 other centres, 3 could not participate for various reasons and 6 did not respond.

For most centres all of the patients were included. In 2 centres not all patients could be included within the inclusion period. Therefore, a random selection of patients was made to prevent bias (selection on alphabetical order or order of appearance at the outpatient clinic).

Data of a total of 216 patients were received. Thirty‐three patients were excluded for the following reasons: no early treatment N = 11, most recent DXA scan \<age 18 years *N* = 11, or significant co‐morbidity that might affect BMD *N* = 11, resulting in a total number of 183 to be analysed.

The characteristics of the included patients are presented in Table [1](#jimd12177-tbl-0001){ref-type="table"}. Based on the Phe concentration before diagnosis and/or the natural protein intake, most of the included patients have severe PAH deficiency. The mean individual Phe concentration the year before the recent DXA was performed showed a wide range, with a median for the group of 775 μmol/L.[2](#jimd12177-bib-0002){ref-type="ref"}, [3](#jimd12177-bib-0003){ref-type="ref"}, [4](#jimd12177-bib-0004){ref-type="ref"}

###### 

Characteristic of included patients

  Continuous data                                                                                                                    N       Median (range)                      
  ---------------------------------------------------------------------------------------------------------------------------------- ------- ----------------------------------- -------
  Age at data collection (years)                                                                                                     183     32 (19‐53)                          
  Age most recent DXA (years)                                                                                                        183     28 (18‐46)                          
  Recent BMI                                                                                                                         179     24.9 (17.5‐49)                      
  Mean Phe the year before the most recent DXA (μmol/L)                                                                              168     775 (61‐1816)                       
  **Categorical data**                                                                                                               **N**                                       **%**
  Gender                                                                                                                             183     Male                                42
  Disease severity based on Phe before treatment[1](#jimd12177-bib-0001){ref-type="ref"}, [2](#jimd12177-bib-0002){ref-type="ref"}   87      Classic PKU (Phe [\>]{.ul}1200)     68
  Mild PKU (Phe \>600 and \<1200)                                                                                                    22                                          
  Mild hyperphe (Phe [\<]{.ul}600)                                                                                                   10                                          
  Natural protein intake                                                                                                             183     Missing or not adherent to a diet   16
  Severe protein restriction ([\<]{.ul}10 g/day)                                                                                     24                                          
  Moderate protein restriction (\>10 to 20 g/day)                                                                                    21                                          
  Mild protein restriction (\>20 to 40 g/day)                                                                                        16                                          
  Protein intake \> recommended intake (\>40 g/day)[a](#jimd12177-note-0004){ref-type="fn"}                                          23                                          
  Sapropterin dichloride use                                                                                                         167     Yes                                 14
  No (not tested or unresponsive)                                                                                                    86                                          
  Low vitamin D concentration (25‐OH vitamin D \<50 nmol/L)                                                                          173     Yes                                 32
  Vitamin D supplementation                                                                                                          162     Yes                                 26
  Calcium supplementation                                                                                                            161     Yes                                 19
  (ex) Smoker status                                                                                                                 106     Yes                                 22
  Alcohol consumption (on average \>2 units/day)                                                                                     106     Yes                                 26

Abbreviations: BMI, body mass index; DXA, dual‐energy X‐ray absorptiometry; PKU, phenylketonuria.

An amount of \>40 g was based on the safe amount of protein of 0.8 g/kg/day according to FAO/WHO/UNU with some patients weighing around 50 kg.

Most BMD results were available for the spinal level. Mean BMD *Z*‐scores were significantly lower in PKU patients compared to the reference population for all skeletal sites except the radius. The lowest result was seen for the spine with a mean *Z* score of −0.527 ([+]{.ul}1.030). Frequency of low BMD (defined as a *Z*‐score ≤−2) was observed in 1.6%‐5.5% with the maximum being observed at the spinal level (Table [2](#jimd12177-tbl-0002){ref-type="table"}).

###### 

Mean, median BMD *Z*‐scores, and % low BMD measured at several skeletal sites

  Skeletal site                                        N     Mean *Z*‐score ([+]{.ul}1 SD)   Median *Z*‐score (range)   Compared to general population[b](#jimd12177-note-0007){ref-type="fn"}   Number (%) low BMD[c](#jimd12177-note-0008){ref-type="fn"}
  ---------------------------------------------------- ----- ------------------------------- -------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------
  Lumbar                                               181   −0.527 ([+]{.ul} 1.030)         −0.600 (−2.8;2.6)          *P* \< .0000[\*](#jimd12177-note-0009){ref-type="fn"}                    10 (5.5)
  Femoral neck                                         111   −0.324 ([+]{.ul} 0.913)         −0.400 (−2.4;2.0)          *P* = .0003[\*](#jimd12177-note-0009){ref-type="fn"}                     4 (3.6)
  Total proximal femur                                 128   −0.262 ([+]{.ul} 0.925)         −0.300 (−2.4;2.9)          *P* = .002[\*](#jimd12177-note-0009){ref-type="fn"}                      2 (1.6)
  Radius                                               55    −0.298 ([+]{.ul} 1.176)         −0.400 (−3.2;1.8)          *P* = .065                                                               3 (6)
  Total body[a](#jimd12177-note-0006){ref-type="fn"}   88    ‐                               −0.400 (−5.9;2.7)          *P* = .002[\*](#jimd12177-note-0009){ref-type="fn"}                      4 (5)

Abbreviation: BMD, bone mineral density.

Not normally distributed.

Mean *Z*‐score= 0.

Defined as *Z*‐score [\<]{.ul}−2.[14](#jimd12177-bib-0014){ref-type="ref"}

Significantly different from the general population (*P* \< .05) after post‐hoc adjustment of *P* value by Bonferroni method (multiplying *P* value by the number of tests (5)).

No statistically significant differences were found in possible risk factors between patients with low BMD and patients with a BMD within normal range (Table [3](#jimd12177-tbl-0003){ref-type="table"}).

###### 

Comparison of possible risk factors between patients with low BMD (*Z*‐score [\<]{.ul}−2) and patients with BMD within normal range (*Z*‐score \>−2)

  Continuous data                                                                             Low BMD                             Normal BMD             *P* (Mann‐Whitney *U* test)                                
  ------------------------------------------------------------------------------------------- ----------------------------------- ---------------------- --------------------------------------------------- ------ ------
  Age most recent DXA (year)                                                                  10                                  27.5                   171                                                 28.0   .864
  Recent BMI                                                                                  10                                  21.7                   167                                                 24.9   .053
  Mean Phe the year before the recent DXA (μmol/L)                                            10                                  800                    156                                                 775    .573
  **Categorical data**                                                                        **Low BMD N (%)**                   **Normal BMD N (%)**   ***P* (Fisher\'s Exact test)**                             
  Gender M                                                                                    8 (80)                              68 (40)                .018[**\***](#jimd12177-note-0012){ref-type="fn"}          
  Sapropterin dichloride use yes                                                              1 (11)                              22 (14)                \>.99                                                      
  Low vitamin D concentration yes                                                             5 (50)                              50 (31)                .294                                                       
  Vitamin D supplementation yes                                                               3 (38)                              39 (26)                .434                                                       
  Calcium supplementation yes                                                                 3 (38)                              27 (18)                .174                                                       
  (ex) Smoker status yes                                                                      0                                   23 (23)                .574                                                       
  Alcohol consumption (on average \>2 units/day) yes                                          2 (50)                              25 (25)                .272                                                       
  Natural protein intake                                                                      Missing or not adherent to a diet   3 (30)                 27 (16)                                             .588   
  Severe protein restriction ([\<]{.ul}10 g/day)                                              1 (10)                              42 (25)                                                                           
  Moderate protein restriction (\>10 to 20 g/day)                                             1 (10)                              35 (21)                                                                           
  Mild protein restriction (\>20 to 40 g/day)                                                 2 (20)                              28 (16)                                                                           
  protein intake \> recommended intake (\>40 g/day)[a](#jimd12177-note-0011){ref-type="fn"}   3 (30)                              39 (23)                                                                           

Abbreviations: BMD, bone mineral density; BMI, body mass index; DXA, dual‐energy X‐ray absorptiometry.

An amount of \>40 g was based on the safe amount of protein of 0.8 g/kg/day according to FAO/WHO/UNU with some patients weighing around 50 kg.

Not significant (*P*  [\>]{.ul} .05) after post‐hoc adjustment of *P* value by Bonferroni method (multiplying *P* value by the number of tests (11)).

Fractures were described in 30 patients (16.4%), which is significantly lower than the estimated age‐standardised fracture prevalence of 38.2% (*P* \< .000) as described for England.[27](#jimd12177-bib-0027){ref-type="ref"} Of those patients who had experienced a fracture, 7 sustained more than 1 fracture. There was insufficient data on which fractures were fragility fractures. There was no significant difference in mean LBMD *Z*‐score between patients with fractures and patients without known fractures (*P* = .97).

4. DISCUSSION {#jimd12177-sec-0006}
=============

This multicentre study of BMD in adult ETPKU patients shows that, although the mean BMD in ETPKU patients is significantly lower compared to the general population, BMD is within normal range in most patients. The prevalence of low BMD is at most observed at the lumbar spine in 5.5% of patients, which is lower than described in the meta‐analysis by Demirdas et al and other previous studies.[7](#jimd12177-bib-0007){ref-type="ref"}, [8](#jimd12177-bib-0008){ref-type="ref"}, [10](#jimd12177-bib-0010){ref-type="ref"}, [11](#jimd12177-bib-0011){ref-type="ref"}, [12](#jimd12177-bib-0012){ref-type="ref"}, [13](#jimd12177-bib-0013){ref-type="ref"} This difference could be explained by the fact that most studies included in the meta‐analysis focused on a combination of both paediatric and adult PKU patients. Assessing BMD in children is hampered by several factors and it is known that low BMD might be overestimated in children with a chronic illness.[16](#jimd12177-bib-0016){ref-type="ref"}, [17](#jimd12177-bib-0017){ref-type="ref"} Also in the study of De Groot et al, low BMD was described in only 6% of adult patients while the percentage tended to be higher in children.[7](#jimd12177-bib-0007){ref-type="ref"} The only previous study which focused exclusively on BMD in adult PKU patients, used other definitions (osteopenia and osteoporosis; not according to the current ISCD definition) but a *Z*‐score [\<]{.ul}−2.5 was detected in 6.5%.[15](#jimd12177-bib-0015){ref-type="ref"} In addition, more recent studies that focused on BMD in both children and adults found low BMD defined as *Z*‐score [\<]{.ul}−2 in 4.5% to 7.4% of the total group of PKU patients.[28](#jimd12177-bib-0028){ref-type="ref"}, [29](#jimd12177-bib-0029){ref-type="ref"} As the present study focuses on adults who are expected to have achieved their peak bone mass,[18](#jimd12177-bib-0018){ref-type="ref"} this is probably a more reliable reflection of BMD in PKU.

4.1. Risk factors for low BMD {#jimd12177-sec-0007}
-----------------------------

In our study population no risk factors for low BMD could be identified. This is in agreement with other studies.[8](#jimd12177-bib-0008){ref-type="ref"}, [15](#jimd12177-bib-0015){ref-type="ref"} The prediction model described by Coakley et al, although based on a small number of patients, found dietary factors like compliance, medical food prescriptions, and vitamin D intake to be of influence.[28](#jimd12177-bib-0028){ref-type="ref"} In the present study, it was not possible to draw conclusions on the exact amount of natural protein intake and medical food protein but an association with non‐adherence to diet, low vitamin D concentration, or vitamin D supplementation was not found. Some studies show that deficiencies in essential fatty acids can be seen in PKU, but there is limited evidence that this might be related to BMD in PKU.[29](#jimd12177-bib-0029){ref-type="ref"}, [30](#jimd12177-bib-0030){ref-type="ref"} Our study did not investigate this.

4.2. Fracture risk {#jimd12177-sec-0008}
------------------

Fracture prevalence in our population was lower than the age‐standardised fracture prevalence as described for the population of England.[27](#jimd12177-bib-0027){ref-type="ref"} It is reasonable to consider that this is more or less comparable with the prevalence of fractures in Europe. The low fracture rate found in this study could be explained by several reasons. Most importantly, in view of the retrospective design of this study, the number of fractures may have been underestimated. Other reasons might be a difference in participation in high fracture risk activities such as specific sports between ETPKU patients and the general population[27](#jimd12177-bib-0027){ref-type="ref"} which was not evaluated in this study. Previous studies focusing on fractures in PKU reported a comparable risk to the general population as well as a higher fracture risk above age 8 detected in a very young group of PKU patients measured by parent or self‐report.[29](#jimd12177-bib-0029){ref-type="ref"}, [31](#jimd12177-bib-0031){ref-type="ref"}

BMD is not the only factor that determines the risk of fractures, to assess the fracture probability in the general population other risk factors should be taken into account.[14](#jimd12177-bib-0014){ref-type="ref"}, [19](#jimd12177-bib-0019){ref-type="ref"}, [20](#jimd12177-bib-0020){ref-type="ref"} The Fracture Risk Assesment Tool (Frax) is available for fracture risk assessment above age 40 years.[19](#jimd12177-bib-0019){ref-type="ref"}

4.3. Recommendations {#jimd12177-sec-0009}
--------------------

Altogether, most ETPKU patients have a BMD within normal range, with only a maximum of 5.5% having a low BMD. As mean BMD is lower compared to the general population, the prevalence of low BMD might be higher in PKU patients \>35‐40 years of age, when bone mass is known to decline.[18](#jimd12177-bib-0018){ref-type="ref"}

With the present data it can be argued that a DXA scan should be requested in PKU patients who have an age \>35‐40 years or in case of additional risk factors for fractures like prolonged immobility, hypogonadism, chronic use of steroids, malabsorption, alcohol abuse, previous fragility fractures, or other conditions that cause an increased fracture risk.[14](#jimd12177-bib-0014){ref-type="ref"}, [18](#jimd12177-bib-0018){ref-type="ref"}, [19](#jimd12177-bib-0019){ref-type="ref"} The European PKU guideline advices (best practice based) to perform a first DXA scan in adolescence.[3](#jimd12177-bib-0003){ref-type="ref"}, [4](#jimd12177-bib-0004){ref-type="ref"} Based on the present study it is a consideration to perform the first DXA scan in a well regulated PKU patient without further risk factors for fractures not in adolescence but at an age \>35‐40 years.

4.4. Strengths and limitations {#jimd12177-sec-0010}
------------------------------

The strength of the present study is the relatively large number patients, the fair proportion of patients with an age in their fourth decade, and the participation of centres from different European countries, making the study population representative of the European ETPKU population. In addition, the study population included many patients with severe PKU (based on Phe before start of treatment or natural protein intake).[2](#jimd12177-bib-0002){ref-type="ref"}, [3](#jimd12177-bib-0003){ref-type="ref"}, [4](#jimd12177-bib-0004){ref-type="ref"}

However, all patients were seen in a centre specialised in PKU, making this a relatively well monitored population. Therefore the results might not be applicable to less regulated patients.

Most participating centres routinely performed a DXA scan in all their patients, some centres only made a DXA scan in a selection of patients. This might have caused bias in the prevalence of low BMD. However, it is more likely that only the patients who are thought to be at risk for low BMD will be selected for a DXA scan. In that case, the reported prevalence of low BMD is an overestimation.

Only the most recent DXA scans were selected for analysis as BMD was thought to be more relevant in older patients. It could be argued that in patients with multiple DXA scans, a result of low BMD would result in a change of treatment influencing the most recent DXA. However, no factors of influence could be identified, making less likely that interventions like vitamin D supplementation or a change in diet directed by an earlier DXA scan resulted in an improved BMD.

Due to the low prevalence of low BMD, the total number of patients with low BMD was 10, hampering additional analysis focusing on risk factors. Because of this small number a multiple regression model was not considered as a most suitable test.

As dietary factors were derived from patient charts, the data were not complete enough to draw conclusions on total protein and medical food protein. Preferably dietary diaries filled in by patients should be used to correlate BMD with dietary factors.

The described fracture prevalence was based on chart studies which are less reliable than an observational study or assessment of patient reported fracture risk.

Although the study included some of the oldest ETPKU patients \>40 years of age, predictions on BMD in older age cannot be made. As bone loss occurs with advancing age[18](#jimd12177-bib-0018){ref-type="ref"}, [19](#jimd12177-bib-0019){ref-type="ref"} future studies in elderly, ETPKU patients are warranted to assess how often low BMD is seen in advancing age and whether these patients have an increased fracture risk.

5. CONCLUSION {#jimd12177-sec-0011}
=============

Mean BMD in early treated adult PKU patients is lower than in the general population but the frequency of low BMD is at maximum 5.5%. DXA scans should be done in well controlled PKU patients \>35‐40 years of age and in those PKU patients considered to be at increased risk for fractures.
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